Finerenone was associated with early and sustained reductions in systolic blood pressure among patients with heart failure with moderately reduced or preserved ejection fraction, researchers reported.The CV benefits of finerenone (Kerendia, Bayer), a nonsteroidal selective mineralocorticoid receptor antagonist, among patients with HF with moderately reduced EF (HFmrEF) or HFpEF were consistent,